February 27, 2020 / 8:43 PM / in a month

BRIEF-Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin in Cancer Pain Trial

Feb 27 (Reuters) - Sorrento Therapeutics Inc:

* SORRENTO THERAPEUTICS PRESENTS INTERIM POSITIVE RESULTS OF PHASE 1B RESINIFERATOXIN (RTX) IN CANCER PAIN TRIAL

* SORRENTO THERAPEUTICS - STUDY IS COMPLETING ENROLLMENT OF AN ADDITIONAL 25 UG EXPANSION DOSE COHORT

* SORRENTO THERAPEUTICS INC - THREE SUBJECTS AT HIGHER DOSES HAD RAPID AND MARKED PAIN REDUCTION AFTER TREATMENT

* SORRENTO THERAPEUTICS - ONE ADDITIONAL COHORT WAS ADDED TO FURTHER EVALUATE A 25 UG DOSE FOR UPCOMING PHASE 3 STUDIES

* SORRENTO THERAPEUTICS INC - INITIAL EXPECTATIONS FOR SAFETY AND EFFICACY HAVE BEEN MET FOR PHASE 1B STUDY

* SORRENTO THERAPEUTICS - BASED ON FULL STUDY RESULTS DOSE WILL BE SELECTED FOR RTX TO PROCEED TO PHASE 3 PIVOTAL TRIALS IN PATIENTS WITH ADVANCED CANCER PAIN

* SORRENTO THERAPEUTICS - OPTIMAL DOSE SELECTION WILL FOLLOW ASSESSMENT OF ADDITIONAL DOSE GROUP IN WHICH 25 UG IS ALSO BEING EVALUATED

* SORRENTO THERAPEUTICS INC - A PIVOTAL PHASE 3 TRIAL IS BEING PLANNED USING EPIDURAL RTX FOR SEVERE PAIN STATES ASSOCIATED WITH ADVANCED DISEASE

* SORRENTO THERAPEUTICS - SAFETY IN HIGHER DOSE COHORT IS EXPECTED TO SUPPORT TESTING RTX EPIDURAL ADMINISTRATION IN OTHER ADVANCED NON-CANCER DISEASE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below